Treatment of IgG4-Related Disease With Revlimid and Rituximab (TIGR2)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02705638|
Recruitment Status : Completed
First Posted : March 10, 2016
Last Update Posted : July 8, 2019
|Condition or disease||Intervention/treatment||Phase|
|Immunoglobulin G Subclass 4 Related Disease IgG4-related Disease Autoimmune Pancreatitis IgG4-related Sclerosing Cholangitis Retroperitoneal Fibrosis||Drug: Rituximab Drug: Lenalidomide||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||6 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Treatment of IgG4-Related Disease With Revlimid and Rituximab: The TIGR2 Trial|
|Study Start Date :||April 2016|
|Actual Primary Completion Date :||April 2019|
|Actual Study Completion Date :||April 2019|
Experimental: Rituximab and Lenalidomide
All subjects will receive Rituxan 1,000 mg intravenously on days 1 and 15, as well as Revlimid 20 mg orally per day on days 1-21, 29-49, and 57-77.
All subjects will receive Rituxan 1,000 mg intravenously on days 1 and 15.
Other Name: Rituxan
All subjects will receive Revlimid 20 mg orally per day on days 1-21, 29-49, and 57-77.
Other Name: Revlimid
- Number of subjects in remission for Immunoglobulin G subclass 4 Related Disease at 24 months [ Time Frame: 24 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02705638
|United States, Minnesota|
|Mayo Clinic in Rochester|
|Rochester, Minnesota, United States, 55905|
|Principal Investigator:||Mark D Topazian, MD||Mayo Clinic|